CD274 and adenocarcinoma: Although there is data to use PD-L1 as a predictive factor for anti PD-1 therapy in the palliative setting [57,58], current evidence of immunotherapy in locally advanced adenocarcinomas of distal oesophagus and GOJ does not support the use of PD-L1 expression as a predictive marker since the benefit of nivolumab in the CheckMate 577 trial was independent of PD-L1 expression [15].